Tyvaso Dpi (Treprostinil) Patent Expiration, LOE Window & CMS Spending
Tyvaso Dpi (Treprostinil) by United Therapeutics: FDA Orange Book core substance LOE 2028-12-15 (last listed 2042-02-03), 0 AB generics, $812.0M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | United Therapeutics |
| FDA Application & Pathway | N214324 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2028-12-15 |
| Last Listed Patent or Exclusivity Date | 2042-02-03 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $812.0M |
| 2024 Medicare Part D Spend | $728.8M |
| 2024 Medicaid Spend | $83.3M |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 16.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for United Therapeutics across sibling Meru public-data platforms.